(Q37764078)

22 August 2017

1 reference

title

Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome: what are the risks and can they be reduced? (English)

1 reference

polycystic ovary syndrome

22 August 2017

0 references

1 reference

based on heuristic

inferred from title

cardiovascular disease

1 reference

1 reference

J Tomlinson

1

1 reference

22 August 2017

A Millward

series ordinal

2

1 reference

22 August 2017

E Stenhouse

series ordinal

3

1 reference

22 August 2017

J Pinkney

series ordinal

4

1 reference

22 August 2017

1 May 2010

1 reference

22 August 2017

1 reference

22 August 2017

27

1 reference

22 August 2017

5

1 reference

22 August 2017

498-515

1 reference

Standards of medical care in diabetes--2010.

22 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

The prevalence of polycystic ovaries in women with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Prevalence of polycystic ovarian changes and polycystic ovary syndrome in premenopausal women with treated type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Diagnosis and Classification of Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Hirsutism and acne in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

The diagnosis of polycystic ovary syndrome: the criteria are insufficiently robust for clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Dietary therapy in polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Psychological benefits of a high-protein, low-carbohydrate diet in obese women with polycystic ovary syndrome--a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

The effect of a hypocaloric diet with and without exercise training on body composition, cardiometabolic risk profile, and reproductive function in overweight and obese women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Metformin in polycystic ovary syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

An observational study of reduction of insulin resistance and prevention of development of type 2 diabetes mellitus in women with polycystic ovary syndrome treated with metformin and diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughou

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

The effects of Diane-35 and metformin in treatment of polycystic ovary syndrome: an updated systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Mevastatin inhibits ovarian theca-interstitial cell proliferation and steroidogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Polycystic ovary syndrome: a follow-up study on diabetes mellitus, cardiovascular disease and malignancy 15-25 years after ovarian wedge resection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Association of variants in the fat mass and obesity associated (FTO) gene with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Global adiposity rather than abnormal regional fat distribution characterizes women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.02994.X

10.1111/J.1464-5491.2010.02994.X

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference